Healthcare / BiotechnologyNasdaqCM
$24.71
-1.50 (-5.72%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-30.4M · quality 66.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$287M
P/E
N/A
•EV/EBITDA
N/A
•ROE
128.9%
↑Gross Margin
N/A
•Debt/Equity
-0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-873.5%
FCF / Net income
0.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.5M · net income $-242.0M · FCF $-30.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $3.5M | $3.5M | $10.7M | — | $12.5M | — | — |
| Net Income | $-242.0M | $-242.0M | $-63.6M | $-43.0M | $-36.0M | $-54.6M | $-32.7M |
| EBITDA | $-41.6M | $-41.6M | $-24.1M | $-41.1M | $-42.4M | $-52.3M | $-30.9M |
| EPS | -32.37 | -32.37 | -21.67 | -21.33 | -15.60 | -33.15 | — |
| Operating Margin | -1210.6% | -1210.6% | -239.7% | — | -354.7% | — | — |
| Net Margin | -6960.8% | -6960.8% | -596.6% | — | -288.0% | — | — |
| Balance Sheet | |||||||
| Debt/Equity | -0.04 | -0.04 | -0.40 | 0.09 | 0.07 | — | — |
| Current Ratio | 11.91 | 11.91 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-30.4M | $-30.4M | $-17.7M | $-40.8M | $-44.9M | $-50.1M | $-30.0M |
| Returns | |||||||
| ROE | 128.9% | 128.9% | 297.3% | -113.5% | -47.4% | -49.8% | -69.2% |
| Valuation | |||||||
| P/B | — | — | — | 0.56 | 0.28 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | -67.4% | -67.4% | — | — | — | — | — |
| EPS Growth | -49.4% | -49.4% | -1.6% | -36.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+191.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-21.67 → -32.37
Residual
+191.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.